Genitourinary Cancers | Specialty

Treating Intermediate and Favorable-Risk RCC

January 29th 2016

Prognostic and Predictive Factors in Renal Cell Carcinoma

January 29th 2016

FDA Grants Cabozantinib Priority Review for RCC

January 28th 2016

The FDA has granted a priority review designation to cabozantinib as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Delayed Decision on CINV Therapy, Priority Review in RCC, and CSS Highlights

January 21st 2016

FDA Grants Priority Review to Lenvatinib/Everolimus Combo for RCC

January 18th 2016

The FDA has granted a priority review designation to the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following one prior VEGF-targeted therapy.

Lenvatinib/Everolimus Combo Submitted for Approval in Advanced RCC

January 15th 2016

Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.

High T-Cell Diversity Linked to Better Prognosis in mRCC

January 14th 2016

The VEGFR inhibitor pazopanib was efficacious independent of T-cell receptor–gamma entropy in metastatic renal cell carcinoma setting.

Dramatic Changes on Horizon in Renal Cell Carcinoma

January 12th 2016

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Cory Abate-Shen on Bladder Cancer Modeling

January 11th 2016

Cory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.

Oral HDAC Inhibitor Improves Antitumor Activity of IL-2 in mRCC

January 11th 2016

A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.

Nivolumab's Survival Benefit Sustained Across RCC Subgroups

January 11th 2016

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

Atezolizumab Update Affirms Activity in Bladder Cancer

January 9th 2016

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

First Checkpoint/Chemo Combo Study for Urothelial Cancer Falls Short

January 9th 2016

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer

January 9th 2016

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

January 9th 2016

Elizabeth Plimack, MD, MS, Associate Professor, Director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Choueiri on Significance of CheckMate-025 Study for RCC

January 8th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.

Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer

January 8th 2016

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.

Expert Predicts PD-1/PD-L1 Agents as Backbone of Combination Therapy in RCC

January 6th 2016

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Cabozantinib Improves PFS Across High-Risk RCC Subgroups

January 4th 2016

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

ESMO Asia Congress, Alcohol-Free Docetaxel Approved, and More

December 31st 2015